Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Net Cash Flow (2019 - 2025)

AVITA Medical's Net Cash Flow history spans 7 years, with the latest figure at -$5.2 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 12.86% year-over-year to -$5.2 million; the TTM value through Dec 2025 reached -$3.8 million, up 52.81%, while the annual FY2025 figure was -$3.8 million, 52.81% up from the prior year.
  • Net Cash Flow reached -$5.2 million in Q4 2025 per RCEL's latest filing, down from $3.2 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $55.1 million in Q1 2021 to a low of -$50.2 million in Q3 2021.
  • Average Net Cash Flow over 5 years is -$4.2 million, with a median of -$3.6 million recorded in 2024.
  • Peak YoY movement for Net Cash Flow: surged 822.38% in 2021, then plummeted 629.74% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$50.2 million in 2021, then soared by 88.66% to -$5.7 million in 2022, then crashed by 404.57% to -$28.7 million in 2023, then surged by 84.03% to -$4.6 million in 2024, then fell by 12.86% to -$5.2 million in 2025.
  • Per Business Quant, the three most recent readings for RCEL's Net Cash Flow are -$5.2 million (Q4 2025), $3.2 million (Q3 2025), and -$2.7 million (Q2 2025).